KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2016 - 2025)

Alnylam Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 111543000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 233.17% year-over-year to 111543000.0; the TTM value through Dec 2025 reached 319698000.0, up 214.93%, while the annual FY2025 figure was 313747000.0, 212.79% up from the prior year.
  • Income from Continuing Operations reached 111543000.0 in Q4 2025 per ALNY's latest filing, down from 292683000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 292683000.0 in Q3 2025 to a low of 405920000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 119134050.0, with a median of 155985500.0 recorded in 2023.
  • The largest YoY upside for Income from Continuing Operations was 362.33% in 2025 against a maximum downside of 292.43% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 258460000.0 in 2021, then rose by 19.72% to 207493000.0 in 2022, then surged by 33.55% to 137870000.0 in 2023, then surged by 39.24% to 83763000.0 in 2024, then soared by 233.17% to 111543000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Income from Continuing Operations are 111543000.0 (Q4 2025), 292683000.0 (Q3 2025), and 66277000.0 (Q2 2025).